Oncology Central

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?


In one of the most significant breakthroughs in cancer treatment, recent studies have demonstrated the ability of immunotherapy involving blockade of CTLA-4 and PD-1 checkpoint receptors on T cells to induce deep and durable anti-tumor responses [1]. PD-1 blockade is an especially promising approach with activity across multiple cancer types. However, the actual response rates are relatively low, for example, approximately 20% in unselected lung cancer patients [2,3].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.